Skip to main content
AprilBio Co.,Ltd. logo

AprilBio Co.,Ltd. — Investor Relations & Filings

Ticker · 397030 ISIN · KR7397030008 KO Professional, scientific and technical activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2024-11-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 397030

About AprilBio Co.,Ltd.

http://www.aprilbio.com/en/

AprilBio is a biotechnology company that develops innovative biologic drugs, including therapeutic antibodies and recombinant proteins. The company's core is its proprietary SAFA (anti-Serum Albumin Fab-Associated) platform technology, which utilizes an albumin-binding antibody fragment to create long-acting therapeutics. This platform is designed to enhance the efficacy, safety, and plasma half-life of drug candidates while minimizing adverse effects. AprilBio's research and development pipeline focuses on addressing unmet medical needs in therapeutic areas such as autoimmune diseases, oncology, and other inflammatory and rare diseases. The company advances new drug candidates through early clinical development stages for potential technology transfer.

Recent filings

Filing Released Lang Actions
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'AprilBio' (주식회사 에이프릴바이오) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial data, business operations, pipeline status, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding an upcoming Investor Relations (IR) event (a conference participation). It provides details such as date, location, and purpose, but it is not the presentation itself. According to the 'Menu vs Meal' rule, an announcement of an event or report is classified as a Regulatory Filing (RNS) when it does not fit into more specific categories like RPA (which is typically for report publication). Since this is a notice of an IR event, RNS is the appropriate fallback category.
2024-11-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Ji Su-seon) of AprilBio. This type of filing is a standard regulatory requirement for reporting insider transactions or changes in share ownership by company directors and executives, which corresponds to the 'Director's Dealing' category.
2024-10-21 Korean
전환청구권행사 (제1회차)
Share Issue/Capital Change Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (CB). This action results in the issuance of new shares, which directly impacts the company's capital structure. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2024-10-02 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership (acquisitions/disposals), and the relationship between the reporter and the issuer (AprilBio). This falls under the 'Major Shareholding Notification' category.
2024-09-11 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal 'Report of Stock Option Grant' (주식매수선택권 부여에 관한 신고) filed with the Financial Supervisory Service (FSS) in South Korea. It details the issuance of stock options to specific employees/executives, including the number of shares, exercise price, and vesting conditions. This type of filing is a regulatory requirement for listed companies to disclose changes in capital structure or equity-based compensation. Since it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), and it is a standard regulatory disclosure, it falls under the 'Regulatory Filings' category.
2024-09-11 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.